2024
A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors
Ouattara S, Hien D, Nao E, Paré P, Guissou E, Cohuet A, Morlais I, Yerbanga R, Dabiré K, Ouédraogo J, Mouline K, Lefèvre T. A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors. Malaria Journal 2024, 23: 135. PMID: 38711028, PMCID: PMC11075210, DOI: 10.1186/s12936-024-04969-0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnophelesFeeding BehaviorFemaleHumansMalaria, FalciparumMosquito VectorsPlasmodium falciparumConceptsDirect membrane feeding assaysGametocyte densityHuman-to-mosquito transmissionDonor bloodLow gametocyte densitiesMembrane feeding assaysPlasmodium falciparum gametocytesTransmission-blocking interventionsWhole bloodInfection rateFalciparum gametocytesInfectious reservoirNaive serumAsymptomatic individualsMosquito infectionHuman donorsRemoval of plasmaEndemic countriesSerumPlasmodiumParasite isolatesInfectionBlood treatmentGametocytesPlasma volume
2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceSeasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R, Issiaka D, Zoungrana C, Sidibe Y, Tapily A, Nikièma F, Sompougdou F, Sanogo K, Kaya M, Yalcouye H, Dicko O, Diarra M, Diarra K, Thera I, Haro A, Sienou A, Traore S, Mahamar A, Dolo A, Kuepfer I, Snell P, Grant J, Webster J, Milligan P, Lee C, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases 2023, 24: 75-86. PMID: 37625434, DOI: 10.1016/s1473-3099(23)00368-7.Peer-Reviewed Original ResearchMeSH KeywordsBurkina FasoChemopreventionChildChild, PreschoolHumansInfantMalariaMalaria VaccinesMalaria, FalciparumMaliSeasonsVaccinationConceptsSeasonal malaria chemopreventionPhase 3 trialClinical malariaAlone groupMalaria Vaccine InitiativeMalaria chemopreventionSeasonal vaccinationProtective efficacyCombined groupPATH Malaria Vaccine InitiativeGlobal Health TrialsPrimary trial endpointSeasonal malaria transmissionSingle intervention groupSupplementary Materials sectionBougouni DistrictCause deathModified intentionProtocol populationControl vaccineMalaria vaccinationMalarial anemiaSevere malariaBlood transfusionHospital admission
2022
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity surveyThe duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone
Cairns M, Barry A, Zongo I, Sagara I, Yerbanga S, Diarra M, Zoungrana C, Issiaka D, Sienou A, Tapily A, Sanogo K, Kaya M, Traore S, Diarra K, Yalcouye H, Sidibe Y, Haro A, Thera I, Snell P, Grant J, Tinto H, Milligan P, Chandramohan D, Greenwood B, Dicko A, Ouedraogo J. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Medicine 2022, 20: 352. PMID: 36203149, PMCID: PMC9540742, DOI: 10.1186/s12916-022-02536-5.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ProtozoanChemopreventionHumansInfantMalariaMalaria VaccinesMalaria, FalciparumPlasmodium falciparumSeasonsVaccinationConceptsDuration of protectionSeasonal malaria chemopreventionClinical malariaMalaria chemopreventionProtective efficacyDifferent vaccine delivery systemsFlexible parametric survival modelsMalaria transmission seasonOverall protective efficacyVaccine delivery systemChild clusteringBooster dosesSeasonal vaccinationMalaria vaccinationSevere malariaDelivery intervalParametric survival modelsCox regressionMalaria vaccinePrimary seriesRecent trialsIntervention groupConclusionsThe efficacyAS01ECox modelEthical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsArtemisininsBurkina FasoChildDrug ResistanceDrug Therapy, CombinationHumansMalariaMalaria, FalciparumNigeriaPlasmodium falciparumConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activitiesField evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning
Das D, Vongpromek R, Assawariyathipat T, Srinamon K, Kennon K, Stepniewska K, Ghose A, Sayeed A, Faiz M, Netto R, Siqueira A, Yerbanga S, Ouédraogo J, Callery J, Peto T, Tripura R, Koukouikila-Koussounda F, Ntoumi F, Ong’echa J, Ogutu B, Ghimire P, Marfurt J, Ley B, Seck A, Ndiaye M, Moodley B, Sun L, Archasuksan L, Proux S, Nsobya S, Rosenthal P, Horning M, McGuire S, Mehanian C, Burkot S, Delahunt C, Bachman C, Price R, Dondorp A, Chappuis F, Guérin P, Dhorda M. Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. Malaria Journal 2022, 21: 122. PMID: 35413904, PMCID: PMC9004086, DOI: 10.1186/s12936-022-04146-1.Peer-Reviewed Original ResearchHaematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
Mansoor R, Commons R, Douglas N, Abuaku B, Achan J, Adam I, Adjei G, Adjuik M, Alemayehu B, Allan R, Allen E, Anvikar A, Arinaitwe E, Ashley E, Ashurst H, Asih P, Bakyaita N, Barennes H, Barnes K, Basco L, Bassat Q, Baudin E, Bell D, Bethell D, Bjorkman A, Boulton C, Bousema T, Brasseur P, Bukirwa H, Burrow R, Carrara V, Cot M, D’Alessandro U, Das D, Das S, Davis T, Desai M, Djimde A, Dondorp A, Dorsey G, Drakeley C, Duparc S, Espié E, Etard J, Falade C, Faucher J, Filler S, Fogg C, Fukuda M, Gaye O, Genton B, Rahim A, Gilayeneh J, Gonzalez R, Grais R, Grandesso F, Greenwood B, Grivoyannis A, Hatz C, Hodel E, Humphreys G, Hwang J, Ishengoma D, Juma E, Kachur S, Kager P, Kamugisha E, Kamya M, Karema C, Kayentao K, Kazienga A, Kiechel J, Kofoed P, Koram K, Kremsner P, Lalloo D, Laman M, Lee S, Lell B, Maiga A, Mårtensson A, Mayxay M, Mbacham W, McGready R, Menan H, Ménard D, Mockenhaupt F, Moore B, Müller O, Nahum A, Ndiaye J, Newton P, Ngasala B, Nikiema F, Nji A, Noedl H, Nosten F, Ogutu B, Ojurongbe O, Osorio L, Ouédraogo J, Owusu-Agyei S, Pareek A, Penali L, Piola P, Plucinski M, Premji Z, Ramharter M, Richmond C, Rombo L, Roper C, Rosenthal P, Salman S, Same-Ekobo A, Sibley C, Sirima S, Smithuis F, Somé F, Staedke S, Starzengruber P, Strub-Wourgaft N, Sutanto I, Swarthout T, Syafruddin D, Talisuna A, Taylor W, Temu E, Thwing J, Tinto H, Tjitra E, Touré O, Tran T, Ursing J, Valea I, Valentini G, van Vugt M, von Seidlein L, Ward S, Were V, White N, Woodrow C, Yavo W, Yeka A, Zongo I, Simpson J, Guerin P, Stepniewska K, Price R. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine 2022, 20: 85. PMID: 35249546, PMCID: PMC8900374, DOI: 10.1186/s12916-022-02265-9.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAntimalarialsChildHumansMalariaMalaria, FalciparumParasitemiaPlasmodium falciparumConceptsUncomplicated P. falciparum malariaSevere anemiaDay 7Nadir hemoglobinParasite clearanceTreatment of uncomplicated P. falciparum malariaDay 3Risk factorsHaematological responseRate of parasite clearanceWorldWide Antimalarial Resistance NetworkArtemisinin-based regimensBackgroundPlasmodium falciparum malariaDelayed parasite clearanceMethodsIndividual patient dataMedian hemoglobin concentrationIndependent risk factorRisk of anemiaArtemisinin-based treatmentsDay 2 post treatmentDay of nadirModerately severe anemiaIndividual patient dataPatient dataMalarial anemia
2021
The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine
Sagara I, Zongo I, Cairns M, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clinical Infectious Diseases 2021, 75: 613-622. PMID: 34894221, PMCID: PMC9464075, DOI: 10.1093/cid/ciab1017.Peer-Reviewed Original ResearchMeSH KeywordsAntibody FormationChildHumansInfantMalariaMalaria VaccinesMalaria, FalciparumPlasmodium falciparumSeasonsVaccinationConceptsFirst booster doseDoses of RTSBooster doseAntibody responseSeasonal vaccinationPost-vaccination antibody titersAnti-circumsporozoite antibodiesBooster antibody responseDiminished antibody responsePrimary vaccination seriesSeasonal malaria chemopreventionSecond booster doseStrong antibody responseIncidence of malariaSubset of childrenEnzyme-linked immunosorbentVaccination seriesBooster dosesMalaria chemopreventionSevere malariaMalaria vaccineAntibody titersLower incidenceVaccinationAS01EContrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum
Hien D, Paré P, Cooper A, Koama B, Guissou E, Yaméogo K, Yerbanga R, Farrell I, Ouédraogo J, Gnankiné O, Ignell R, Cohuet A, Dabiré R, Stevenson P, Lefèvre T. Contrasting effects of the alkaloid ricinine on the capacity of Anopheles gambiae and Anopheles coluzzii to transmit Plasmodium falciparum. Parasites & Vectors 2021, 14: 479. PMID: 34526119, PMCID: PMC8444468, DOI: 10.1186/s13071-021-04992-z.Peer-Reviewed Original ResearchConceptsAnopheles coluzziiAnopheles gambiaeCastor bean Ricinus communisSecondary phytochemicalsKey phenotypic traitsNovel control agentsPlant-derived sugarsAbility of mosquitoesPhenotypic traitsPlasmodium falciparumParasite growth ratePlant sugarsPlant nectarFeeding assaysControl agentsMosquito physiologyGrowth rateAnopheles speciesSensu latoAnopheles gambiae sensu latoColuzziiGambiae sensu latoPutative roleP. falciparum infectionMosquito survivalEffectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite densitySeasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R, Diarra M, Nikièma F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou A, Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouédraogo J, Dicko A, Greenwood B. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2021, 385: 1005-1017. PMID: 34432975, DOI: 10.1056/nejmoa2026330.Peer-Reviewed Original ResearchConceptsUncomplicated malariaProtective efficacyClinical malariaSevere malariaMalaria-related outcomesSeasonal malaria chemopreventionUncomplicated clinical malariaVaccine-alone groupWorld Health Organization definitionPrespecified noninferiority marginMonths of ageMalaria chemopreventionSeasonal vaccinationFirst doseHazard ratioMalaria vaccinationFebrile seizuresHospital admissionCombination groupNoninferiority marginLower incidenceAS01ChemopreventionChildren 5Organization definitionEffect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness
Yaméogo K, Yerbanga R, Ouattara S, Yao F, Lefèvre T, Zongo I, Nikièma F, Compaoré Y, Tinto H, Chandramohan D, Greenwood B, Belem A, Cohuet A, Ouédraogo J. Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness. Malaria Journal 2021, 20: 326. PMID: 34315475, PMCID: PMC8314489, DOI: 10.1186/s12936-021-03855-3.Peer-Reviewed Original ResearchConceptsAddition of azithromycinMalaria chemopreventionSulfadoxine-pyrimethamineGametocyte infectivityAsexual Plasmodium falciparumDirect membrane feeding assaysSeasonal malaria chemopreventionPlacebo-controlled trialPlasmodium falciparum transmissionMembrane feeding assaysInfectivity of gametocytesControl of malariaPresence of malariaMalaria transmission periodDays post treatmentAnopheles gambiae mosquitoesGametocyte prevalenceMethodsThe studyConclusionThis studyMalaria transmissionP. falciparumControl childrenMosquito transmissionAppropriate interventionsChemopreventionPersistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
Beshir K, Diallo N, Somé F, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore O, Coulibaly S, Maurice O, Diarra A, Kaboré J, Kodio A, Togo A, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore Y, Kabore N, Barry N, Soulama I, Sagara I, Sirima S, Ouédraogo J, Djimde A, Sutherland C. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00873-21. PMID: 34060901, PMCID: PMC8284475, DOI: 10.1128/aac.00873-21.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineClinical episodesFirst treatment episodeComplete parasite clearanceDrug treatment groupPlasmodium falciparum parasitemiaQuantitative PCRMalaria transmission intensityEvaluable patientsParasitological efficacyParasite clearanceTreatment failureSubmicroscopic parasitemiaTreatment episodesTreatment outcomesTreatment groupsBetter efficacyDay 42Short intervalsH posttreatmentParasitemiaRegimensPatientsBurkina FasoTransmission intensityHepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2020
Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Tapily A, Issiaka D, Sanogo K, Mahamar A, Sompougdou F, Yerbanga S, Thera I, Milligan P, Tinto H, Ofori-Anyinam O, Ouedraogo J, Greenwood B. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open 2020, 10: e035433. PMID: 32933955, PMCID: PMC7493088, DOI: 10.1136/bmjopen-2019-035433.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionClinical malariaTransmission seasonMalaria chemopreventionSeasonal vaccinationDoses of RTSWeekly active surveillancePlacebo-controlled trialPhase 3 trialMalaria transmission seasonPositive blood filmPrevalence of malariaSubsequent transmission seasonSubset of childrenCombination of vaccinationBooster doseModified intentionPrimary endpointControl vaccineFirst doseMalaria vaccineActive surveillanceCase detectionRabies vaccineHealth facilitiesInvestigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso
Somé FA, Bazié T, Ehrlich HY, Goodwin J, Lehane A, Neya C, Zachari K, Wade M, Ouattara JM, Foy BD, Dabiré RK, Parikh S, Ouédraogo JB. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malaria Journal 2020, 19: 238. PMID: 32631416, PMCID: PMC7339464, DOI: 10.1186/s12936-020-03311-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDay 7 concentrationsSMC administrationMalaria chemopreventionMalaria infectionDay 7 plasma concentrationsHigh malaria transmission seasonBlood spotsFirst monthPfcrt 76TPrevalence of microscopicSubmicroscopic malaria infectionMalaria transmission seasonPlasmodium falciparum infectionPfcrt K76THigh transmission settingsSequential cross-sectional surveysCross-sectional surveyNon-significant trendAmodiaquine metabolismPfmdr1 N86Malaria parasitaemiaFalciparum infectionK76TPlasma concentrationsDifferent distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission
Pigeault R, Isaïa J, Yerbanga R, Dabiré K, Ouédraogo J, Cohuet A, Lefèvre T, Christe P. Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission. Scientific Reports 2020, 10: 10183. PMID: 32576924, PMCID: PMC7311528, DOI: 10.1038/s41598-020-67180-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCanariesCarrier StateChildChild, PreschoolCulexFemaleHumansMalaria, FalciparumMaleMosquito VectorsPlasmodiumVertebratesConceptsGametocyte densityMosquito infection ratesBlood samplesInfection rateNew malaria control strategiesMajor global causeMalaria control strategiesLow parasite burdenGametocyte burdenGametocyte carriersParasite transmissionPlasmodium infectionMosquito transmission potentialRight extremitiesTransmissible stagesParasite burdenMosquito transmissionMalaria parasitesPlasmodium sppGlobal causeTransmission potentialGametocytesVector-borne diseasesDiseaseExtremitiesThe duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data
Bretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D’Alessandro U, Djimde A, Dorsey G, Espié E, Fofana B, González R, Juma E, Karema C, Lasry E, Lell B, Lima N, Menéndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ouédraogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, Guerin P, Okell L. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine 2020, 18: 47. PMID: 32098634, PMCID: PMC7043031, DOI: 10.1186/s12916-020-1494-3.Peer-Reviewed Original ResearchConceptsFirst-line treatmentDuration of chemoprophylaxisPost-treatment prophylaxisIndividual patient dataAS-AQArtemether-lumefantrinePlasmodium falciparum malaria casesPfcrt 76TPatient dataFalciparum malaria casesPotential public health impactHigh transmission areasDuration of protectionLonger protectionPublic health impactTransmission intensityWild-type Pfmdr1Pfmdr1 86YMalaria morbidityClinical incidenceMean durationClinical trialsChemoprevention programMultivariable modelHigh prevalenceIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms